Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 2.655 USD 1.72%
Market Cap: 1.1B USD

Wall Street
Price Targets

IOVA Price Targets Summary
Iovance Biotherapeutics Inc

Wall Street analysts forecast IOVA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IOVA is 8.517 USD with a low forecast of 1.515 USD and a high forecast of 17.85 USD.

Lowest
Price Target
1.515 USD
43% Downside
Average
Price Target
8.517 USD
221% Upside
Highest
Price Target
17.85 USD
572% Upside
Iovance Biotherapeutics Inc Competitors:
Price Targets
APLS
Apellis Pharmaceuticals Inc
38% Upside
688192
Dizal Jiangsu Pharmaceutical Co Ltd
45% Upside
XNCR
Xencor Inc
103% Upside
XFOR
X4 Pharmaceuticals Inc
97% Upside
INSM
Insmed Inc
25% Upside
2157
Lepu Biopharma Co Ltd
99% Upside
ALKS
Alkermes Plc
48% Upside
002007
Hualan Biological Engineering Inc
23% Upside

Revenue
Forecast

Revenue Estimate
Iovance Biotherapeutics Inc

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 4 years is 50%.

N/A
Past Growth
50%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Iovance Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Iovance Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-71%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IOVA's stock price target?
Price Target
8.517 USD

According to Wall Street analysts, the average 1-year price target for IOVA is 8.517 USD with a low forecast of 1.515 USD and a high forecast of 17.85 USD.

What is Iovance Biotherapeutics Inc's Revenue forecast?
Projected CAGR
50%

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 4 years is 50%.

Back to Top